31.98
-0.09(-0.28%)
Currency In USD
| Previous Close | 32.07 |
| Open | 32.14 |
| Day High | 32.55 |
| Day Low | 31.75 |
| 52-Week High | 40.28 |
| 52-Week Low | 25.66 |
| Volume | 212,566 |
| Average Volume | 560,381 |
| Market Cap | 1.79B |
| PE | 28.81 |
| EPS | 1.11 |
| Moving Average 50 Days | 32.18 |
| Moving Average 200 Days | 34.03 |
| Change | -0.09 |
If you invested $1000 in Supernus Pharmaceuticals, Inc. (SUPN) 10 years ago, it would be worth $1,848.55 as of July 06, 2025 at a share price of $31.98. Whereas If you bought $1000 worth of Supernus Pharmaceuticals, Inc. (SUPN) shares 5 years ago, it would be worth $1,356.23 as of July 06, 2025 at a share price of $31.98.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
GlobeNewswire Inc.
Jun 16, 2025 11:00 AM GMT
Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zura
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals
GlobeNewswire Inc.
May 29, 2025 12:30 PM GMT
New video series explores the impact of ADHD on relationships and the role of Qelbree in helping Jay’s ADHD symptom managementROCKVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals is expanding its partnership with TV personality
Supernus Announces Paragraph IV ANDA Filings for Qelbree®
GlobeNewswire Inc.
May 28, 2025 8:05 PM GMT
ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announc